Bimekizumab Safe, Efficacious Over Two Years for Hidradenitis Suppurativa

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 7, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Oct. 7, 2024 -- For patients with hidradenitis suppurativa (HS), bimekizumab is safe and efficacious over two years, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from Sept. 25 to 28 in Amsterdam.

Christos C. Zouboulis, from the European Hidradenitis Suppurativa Foundation in Dessau, Germany, and colleagues presented efficacy and safety data over two years for the pooled BE HEARD I&II (BHI&II) and BE HEARD EXT (BHEXT) trials. Overall, 556 patients were randomly assigned to bimekizumab in BHI&II at baseline, completed 48 weeks, and entered BHEXT; 446 completed 96 weeks in BHEXT.

The researchers found that ≥50 percent HS Clinical Response (HiSCR50)/75/90/100 was achieved by 79.9, 64.0, 42.3, and 30.2 percent of all bimekizumab patients, respectively, at week 48; there was improvement in responses to 85.4, 77.1, 57.6, and 44.2 percent, respectively, at week 96. The mean International HS Severity Score System (IHS4) score among bimekizumab patients was 35.6 ± 31.5 at baseline; the mean percentage change from baseline in IHS4 was −70.3 ± 39.6 and −79.8 ± 28.1 percent at weeks 48 and 96, respectively. The mean draining tunnel (DT) count was 3.8 ± 4.3 among bimekizumab patients at baseline; the mean percentage change from baseline in DTs was −57.5 ± 72.9 and −73.7 ± 45.7 percent at weeks 48 and 96, respectively. Overall, 917 of 995 patients who received one or more doses of bimekizumab experienced a treatment-emergent adverse event (TEAE) over two years. Serious TEAEs were reported in 122 patients, and TEAEs leading to discontinuation were reported in 109.

"These findings are particularly encouraging given the need for new treatment options that offer sustained relief for patients," Zouboulis said in a statement.

Several authors are employees of UCB Pharma, which manufactures bimekizumab and funded the BE HEARD trials.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-10-08 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords